Abstract
Objective To study the apatinib for treatment of advanced non-small cell lung cancer (NSCLC). Methods The data of one patient with advanced NSCLC was analyzed and the related literatures were reviewed to discuss treatment principle for advanced NSCLC, the curative effect and adverse reactions of apatinib in the treatment of advanced NSCLC. Results After first-line treatment failure of tyrosine kinase inhibitor for advanced NSCLC, second-line treatment of apatinib extended progression free survival, but serious adverse reaction appeared in the course of treatment--level 3 hand foot syndrome.There was progress after drug reduction, affecting the overall survival of patients. Conclusions Apatinib may be effective in some patients with advanced NSCLC, which provides a new choice for second-line treatment of advanced NSCLC. Key words: Non-small cell lung cancer; Tyrosine kinase inhibitor; Apatinib; Hand foot syndrome
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call